Compare GPRO & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPRO | RFL |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Real Estate |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.4M | 133.1M |
| IPO Year | 2014 | 2017 |
| Metric | GPRO | RFL |
|---|---|---|
| Price | $1.19 | $1.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 15.3M | 145.0K |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.08 | 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $651,542,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $35.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.57 | $1.12 |
| 52 Week High | $2.73 | $3.96 |
| Indicator | GPRO | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 36.99 |
| Support Level | $0.68 | $1.22 |
| Resistance Level | $1.32 | $1.58 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 4.76 | 32.63 |
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.